Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23889639 | 0.67 | EIF4A1 (0.32) | — | |
| SCHEMBL24180260 | 0.61 | CYP3A4 (0.33) | KMT2AKDM4E | |
| SCHEMBL24426966 | 0.61 | — | — | |
| SCHEMBL12863057 | 0.58 | GAA (0.42) | RAB9ASMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL16751353 | 0.57 | HTT (0.40) | SMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL16298832 | 0.56 | SLC6A2 (0.47) | RAB9ASMN1; SMN2MEN1KMT2ATDP1 | |
| SCHEMBL16298826 | 0.56 | SLC6A2 (0.47) | RAB9ASMN1; SMN2MEN1KMT2ATDP1 | |
| SCHEMBL17054161 | 0.55 | ALDH1A1 (0.56) | TDP1 | |
| SCHEMBL17087121 | 0.54 | ACHE (0.50) | SMN1; SMN2L3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL19468424 | 0.54 | ACHE (0.45) | RAB9ASMN1; SMN2MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150087598-A1 | TREATING MUC1-EXPRESSING CANCERS WITH HELICASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087598-A1 | TREATING MUC1-EXPRESSING CANCERS WITH HELICASE INHIBITORS | MUC1, DDX21, DDX39B | RAB9A 1024/4885SMN1; SMN2 4162/4885L3MBTL1 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.